logo
Plus   Neg
Share
Email

AstraZeneca Reports Detailed Results From Phase III DAPA-HF Trial - Quick Facts

AstraZeneca (AZN.L,AZN) announced that detailed results from the Phase III DAPA-HF trial showed that Farxiga on top of standard of care reduced both the incidence of cardiovascular death and the worsening of heart failure. The topline results announced in the previous month demonstrated that DAPA-HF met the primary endpoint.

Separately AstraZeneca (AZN.L, AZN) presented detailed results from the Phase III THEMIS trial, in which Brilinta plus aspirin reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone. The company said it will work with regulatory authorities to explore an update to the Brilinta label.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Tesla Motors Inc. (TSLA) surged 12% in extended trading session on Wednesday after the luxury electric car maker reported a surprise third-quarter profit, which trumped Wall Street estimates. Looking forward, the company said it is "highly confident" to exceed 360,000 deliveries this year. Palo... Spotify is offering free Google Home Mini speakers to all new and existing Spotify Premium users in the U.S. The music streaming service said Tuesday that the Google Home Mini offer is for all eligible Premium Individual and Premium Family master account users in the U.S. The offer is available through November 15, or until supplies last. Federal Cartridge recalled about 3,100 units of Blackhawk T-Series L2C gun holsters due to injury hazard, a statement published by the U.S. Consumer Product Safety Commission said. The safety switch on the firearm can change its position without the knowledge of the user due to the holster design, causing the gun to fire if the trigger is pulled and pose injury hazard to the user and bystander.
Follow RTT
>